Blog

Head to Head Review: BeyondSpring (NASDAQ:BYSI) versus Editas Medicine (EDIT) – StockNewsTimes


StockNewsTimes

Head to Head Review: BeyondSpring (NASDAQ:BYSI) versus Editas Medicine (EDIT)
StockNewsTimes
It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9
EDIT Stock: Pioneering Genome Editing TechnologyProfit Confidential


ArQule (NASDAQ:ARQL) and Editas Medicine (EDIT) Financial …The Ledger Gazette
Financial Newsletter – ZacksZacks
SEC.gov –SEC.gov
all 45 news articles »

2018-03-24 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.